U.S. ResidentsGLIVEC CONTINUES TO REVOLUTIONIZE THE TREATMENT OF KIT+ GIST
Prior to GLIVEC (imatinib), the prognosis for patients with gastrointestinal stromal tumor (GIST) was poor. Tumor recurrence often followed surgical resection for primary disease. In advanced disease, there were no effective treatment options and survival averaged about 1 year.1,2
Today, data show 3 years of adjuvant GLIVEC is significantly reducing the risk of tumor recurrence following surgery for patients with KIT+ GIST, extending their lives with a 92% overall survival rate at 5 years.3 And, in the treatment of advanced KIT+ GIST, GLIVEC is extending the lives of patients to a median of nearly 5 years, even in the face of disease progression.3,4
Learn more about the benefit of extending adjuvant GLIVEC after KIT+ GIST resection.
GLIVEC: Positively Impacting the Lives of KIT+ GIST Patients
The patient cases to the right illustrate important clinical decision points in KIT+ GIST. Visit them to view information that can help you make informed treatment choices for your patients.
Select case now.
Prescribing GLIVEC
Review the safety profile of GLIVEC here, while getting the basics on dosing, administration, and ways to manage potential side effects.
Get the basics on dosing and administration for GLIVEC here.Prescribing GLIVEC
About GIST
Learn more about GIST, from its cellular origins through its clinical course, and see why a multidisciplinary approach optimizes patient care.
Download a GIST Risk of Recurrence Calculator.
GIST=gastrointestinal stromal tumor.
References
- Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99(1):42-47.
- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-58.
- Glivec® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2012.
- Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-625.
